PMID- 6318979
OWN - NLM
STAT- MEDLINE
DCOM- 19840323
LR  - 20181130
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 44
IP  - 3
DP  - 1984 Mar
TI  - Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth 
      factor receptor monoclonal antibodies.
PG  - 1002-7
AB  - Monoclonal antibodies (MoAbs) were raised against epidermal growth factor (EGF) 
      receptors on a human epidermoid carcinoma cell line, A431. Administration of 
      anti-EGF receptor MoAbs inhibited tumor formation in athymic mice by A431 cells 
      and by another epidermal carcinoma cell line, T222. When one of the same MoAbs 
      was used in therapy against Li-7 (a human hepatoma) and HeLa cells (a cervical 
      carcinoma), tumor growth was not affected. The number of EGF receptors on A431 
      cells was about 100-fold higher than on T222, Li-7, and HeLa cells, suggesting 
      that the number of EGF receptors may not be an important determinant in 
      suppressing tumor growth. Three anti-EGF receptor MoAbs were used in the present 
      studies. MoAbs 528 (immunoglobulin G2a) and 225 (immunoglobulin G1) are capable 
      of competing with EGF for receptor binding and inhibit proliferation of A431 
      cells in culture. The other MoAb, 455 (immunoglobulin G1), is incapable of 
      blocking the binding of EGF to its receptors and has no effect on the 
      proliferation of cultured A431 cells. All three MoAbs inhibited A431 tumor growth 
      in athymic mice, indicating that the antibody isotype and the site of binding on 
      the EGF receptor are not the determinants of antiproliferative activity in vivo. 
      The observation that MoAb against the receptor for EGF is cytostatic rather than 
      cytocidal in vitro against A431 cells, yet completely prevents tumor growth in 
      vivo, suggests that some host animal responses also may be involved in the 
      antitumor effect. MoAbs against growth factor receptors could provide useful 
      immunotherapeutic agents.
FAU - Masui, H
AU  - Masui H
FAU - Kawamoto, T
AU  - Kawamoto T
FAU - Sato, J D
AU  - Sato JD
FAU - Wolf, B
AU  - Wolf B
FAU - Sato, G
AU  - Sato G
FAU - Mendelsohn, J
AU  - Mendelsohn J
LA  - eng
GR  - CA 23052/CA/NCI NIH HHS/United States
GR  - CA 33397/CA/NCI NIH HHS/United States
GR  - GM 17702/GM/NIGMS NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, Cell Surface)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - *Antibodies, Monoclonal
MH  - Carcinoma, Squamous Cell/immunology/*physiopathology/therapy
MH  - Cell Line
MH  - Epidermal Growth Factor/*immunology
MH  - ErbB Receptors
MH  - HeLa Cells/immunology/physiology
MH  - Humans
MH  - Immunotherapy
MH  - Kinetics
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Receptors, Cell Surface/*immunology
MH  - Transplantation, Heterologous
EDAT- 1984/03/01 00:00
MHDA- 1984/03/01 00:01
CRDT- 1984/03/01 00:00
PHST- 1984/03/01 00:00 [pubmed]
PHST- 1984/03/01 00:01 [medline]
PHST- 1984/03/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1984 Mar;44(3):1002-7.